Assembly Biosciences Announces November Conference Participation
SAN FRANCISCO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced participation at various upcoming conferences in November, in addition to its presentation at AASLD on November 11, 2018 in San Francisco.
China Renaissance 6th Healthcare and Lifesciences Leadership Summit – Shanghai, China
Presenter: Derek Small, President and Chief Executive Officer
Date: November 1-2, 2018
International HBV Cure Workshop – Toronto, ON
Presenter: Richard Colonno, PhD, Executive Vice President, Chief Scientific Officer of Virology Operations
Date: November 7, 2018
Stanford Medicine Symposium on HBV and HDV – Foster City, CA
Presenter: Uri Lopatin, MD, Chief Medical Officer
Date: November 8, 2018
Jefferies London Healthcare Conference – London, UK
Presenter: Richard Colonno, PhD, Executive Vice President, Chief Scientific Officer of Virology Operations
Date: November 14-15, 2018
The scientific presentations will focus on targeting HBV core protein to clear infection with the goal of achieving higher cure rates in patients with chronic HBV.
A webcast of the Jefferies presentation will be available in the Events and Presentations section of the Company’s website at www.assemblybio.com.
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live synthetic biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® delivery technology. For more information, visit assemblybio.com.作者: StephenW 时间: 2018-11-2 15:20